Senseonics (NYSE:SENS) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS) in a research note issued to investors on Tuesday. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $2.00 price target on shares of Senseonics in a report on Friday, November 15th.

Senseonics Price Performance

Shares of NYSE:SENS opened at $0.30 on Tuesday. Senseonics has a 12 month low of $0.25 and a 12 month high of $0.75. The stock has a market cap of $181.04 million, a price-to-earnings ratio of -2.34 and a beta of 0.77. The stock’s 50 day moving average price is $0.32 and its 200 day moving average price is $0.38. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38.

Insider Buying and Selling at Senseonics

In related news, CEO Timothy T. Goodnow purchased 315,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were bought at an average price of $0.31 per share, with a total value of $97,650.00. Following the completion of the acquisition, the chief executive officer now owns 11,310,355 shares of the company’s stock, valued at approximately $3,506,210.05. This represents a 2.86 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 3.90% of the stock is owned by corporate insiders.

Institutional Trading of Senseonics

Large investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP acquired a new stake in Senseonics during the 3rd quarter valued at $117,000. Price T Rowe Associates Inc. MD raised its stake in Senseonics by 16.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after purchasing an additional 51,000 shares during the period. Vanguard Group Inc. raised its stake in Senseonics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock valued at $11,963,000 after purchasing an additional 155,715 shares during the period. Cubist Systematic Strategies LLC raised its stake in Senseonics by 25.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after purchasing an additional 85,501 shares during the period. Finally, Geode Capital Management LLC raised its stake in Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after purchasing an additional 179,103 shares during the period. 12.36% of the stock is owned by institutional investors and hedge funds.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.